Nova Laboratories
United Kingdom 3 duplicate records merged Updated 9 July 2026
Nova Laboratories is a finished-dose manufacturer based in United Kingdom. It appears in 176 regulatory filings across 9 regulators, without an active US DMF or CEP on file. Its filings concentrate with NPRA (MY), MHRA (UK) and US FDA. Its GMP standing is certified by MHRA (UK) and US FDA. Its most recent recorded inspection, by US FDA, closed on 23 August 2024 as VAI.
2
registered plants
1 with an FDA FEI number
176
filings
across 9 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 23 August 2024 VAI US FDA
- 12 March 2019 VAI US FDA
- 28 February 2019 VAI US FDA
- 3 March 2016 VAI US FDA
- 6 December 2013 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| WIGSTON, United Kingdom | Not on file |
| United Kingdom, United Kingdom | 3000323524 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| NPRA (MY) | 163 | None |
| MHRA (UK) | 4 | 5 |
| US FDA | 2 | 1 |
| SFDA (Saudi Arabia) | 2 | None |
| AEMPS (ES) | 1 | None |
| EEC_EAEU | 1 | None |
Comparing suppliers?
Choose your molecules and target markets. Nova Laboratories comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 23 August 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates